AI, machine learning offer hope for speeding Alzheimer's development

"Unlearn.AI Inc., of San Francisco, has developed a process to create digital twins of Alzheimer's disease patients in the active-treatment group that predict how they would perform if they weren't given drug. The company's Digenesis process uses historical clinical trial datasets from patients who participated in the control arms of clinical trials to create the twins who are a mash-up of multiple patients in the studies."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Embracing Innovation to Move Forward

Podcasts

Your Digital Twin - UnlearnAI

Podcasts

Using AI Digital Twins for Drug Testing

Dr. Charles Fisher, CEO of Unlearn AI, discusses creating digital clones by using artificial intelligence for use in clinical drug trials.
A fascinating approach to the problem of how to make clinical trials more efficient, and understand more about what may be possible with more and better patient data.
At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.